Prostatitis Signs and Symptoms

Signs and Symptoms

Introduction

A spectrum of disorders that affect men whose symptoms are referable to the lower urogenital tract & perineum

Etiology

Etiologic agents are the same for both acute bacterial prostatitis (ABP) & chronic bacterial prostatitis (CBP) & include E coli (most commonly isolated pathogen), Enterococcus sp, Klebsiella sp, Proteus sp, P aeruginosa, C trachomatis, U urealyticum, T vaginalis
- Immune-deficient or human immunodeficiency virus (HIV) patients may have pathogens such as S typhi, M avium, M tuberculosis, Candida sp, C immitis, B dermatitidis, H capsulatum

Signs and Symptoms

Prominent features are genitourinary, pelvic or rectal pain & lower urinary tract symptoms, eg urinary frequency, urgency, hesitancy, weak stream & straining on urination, dysuria, pain that increased w/ urination

Optimizing metastatic hormone-sensitive prostate cancer treatment in advanced prostate cancer

Assoc Prof. Darren Poon, Assoc Prof. Edmund Chiong, 14 Jan 2021

Metastatic hormone-sensitive prostate cancer (mHSPC) refers to the condition whereby patients have metastatic prostate cancer and no prior hormonal therapy or androgen deprivation therapy (ADT). Typically, patients with mHSPC have been treated with ADT alone, following which, the overwhelming majority develop castration resistance over time and head towards eventual mortality. In recent years, the publication of various landmark trials has prompted dramatic changes in the mHSPC treatment landscape, and had favourably impacted overall survival (OS) in these patients. At a recent webinar, A/Prof Darren Poon, Honorary Consultant in Clinical Oncology, Hong Kong Sanatorium & Hospital, and Honorary Clinical Associate Professor, Department of Clinical Oncology, The Chinese University of Hong Kong, reviewed treatment options in mHSPC, while A/Prof Edmund Chiong, Head and Senior Consultant, Department of Urology, National University Hospital, Singapore, presented a case which was discussed by an esteemed panel of experts. This webinar was jointly organized by the Singapore Society of Oncology and the Singapore Urological Association, and supported by Astellas.